Development of extended zero-order release gliclazide tablets by central composite design

Drug Development and Industrial Pharmacy

Volumn 34, Issue 1, 2008, Pages 33-45

  Vijayalakshmi, P ^a   Devi, V Kusum ^a   Narendra, C ^b   Srinagesh, S ^c  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

^b Visveswarapura Institute of Pharmaceutical Sciences   (India)

^c NONE

Author keywords

Central composite design; Eudragit EPO; Extended release tablets; Gliclazide; Keltone HVCR

Indexed keywords

ALGINIC ACID; EUDRAGIT; GLICLAZIDE; POLYMER;

ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED DRUG RELEASE; DRUG DESIGN; DRUG DIFFUSION; DRUG DOSAGE FORM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; FEASIBILITY STUDY; HARDNESS; INDEPENDENT VARIABLE; KINETICS; MATHEMATICAL ANALYSIS; PH; RESPONSE SURFACE METHOD; RESPONSE VARIABLE; TABLET FORMULATION;

CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; GLICLAZIDE; HARDNESS; HYDROGEN-ION CONCENTRATION; HYPOGLYCEMIC AGENTS; MICROSCOPY, ELECTRON, SCANNING; POLYMERS; SOLUBILITY; SURFACE PROPERTIES; TABLETS;

EID: 38549157946     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701386129     Document Type: Article

References (40)

1. Banker, G. S., & Anderson, N. R. (1987). Tablets. In L. Lachman, H. A. Liberman, & J. L. Kanig (Eds.), The Theory and practice of industrial pharmacy (pp. 293-345). Mumbai: Varghese Publishing House: Mumbai.
2. Campbell, D. B., Laveille, R., & Nathan, C. (1991). The mode of action and clinical pharmacology of gliclazide: A Review. Diab. Res. Clin. Pract., 14, 21-36.
3. Chowdary, K. P. R., & Kamalakara R. G. (2002). Sustained release of nifedipine from mucoadhesive tablets of its solid dispersions in HPMC and HPC. Indian Drugs, 39(4), 225-229.
4. Costa, P., & Sousa Lobo, J. M. (2001). Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci., 13, 123-133.
5. Delrat, P., Paraire, M., & Jochemsen, R. (2002). Complete bioavailability and lack of food effect on pharmacokinetics of gliclazide 30mg modified release in healthy volunteers. Biopharm. Drug Disp., 23, 151-57.
6. Drouin, P. (2000). Diamicron® MR once daily is effective and well tolerated in type 2 diabetes: A double-blind randomized multinational study. J. Diab. Comp., 14, 185-91.
7. Efentakis, M., & Buckton, G. (2002). The effect of erosion and swelling on the dissolution of theophylline from low and high viscosity sodium alginate matrices. Pharm. Dev. Tech., 7(1), 69-77.
8. Efentakis, M., & Koutlis, A. (2001). Release of furosemide from multiple-unit and single-unit preparations containing different viscosity grades of sodium alginate. Pharm. Dev. Tech., 6(1), 91-98.
9. Einig, H., Stieren, B., Buehler, V., & Hollmann, M. (1993). Sustained release tablet of a mixture of alginates and polyacrylates. United states patent-5230901.
10. European Medicines Agency (2006). Note for guidance on stability testing: Stability testing of new drug substances and products (CPMP/ICH/2736/99).
11. Glowka, F. K., Hermann, T. W., & Zabel, M. (1998). Bioavailability of gliclazide from some formulation tablets. Int. J. Pharm., 172, 71-77.
12. Higuchi, T. (1963). Mechanism of sustained action medication: Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci., 52, 1145-1149.
13. Huang, Y., Tsai, Y., Lee, S., Chang, J., & Wu, P. (2005). Optimization of pH-dependent release of nicardipine hydrochloride extended release matrix tablets using response surface methodology. Int. J. Pharm., 289, 87-95.
14. Kadhe, G., & Arasan, R. E. (2002). Advances in drug delivery of oral hypoglycemic agents. Cur. Sci., 83(12), 1539-1543.
15. Korsmeyer, R. W., Doelker, G. E. P., & Peppas, N. A. (1983). Mechanisms of potassium chloride from compressed hydrophilic polymeric matrices: Effect of entrapped air. J. Pharm. Sci., 72, 1189-1191.
16. Kuksal, A., Tiwary, A. K., Jain, N. K., & Jain, S. (2006). Formulation and in vitro, in vivo evaluation of extended-release matrix tablet of zidovudine: Influence of combination of hydrophilic and hydrophobic matrix formers. AAPS Pharm. Sci. Tech., 7(1), Article 1, DOI: 10.1208/pt070101.
17. Lee, P. I. (1984). Novel zero order drug delivery via immobilized nonuniformed drug distribution in glassy hydrogels. J. Pharm. Sci., 73, 1344-1347.
18. Lewis, G. A., Mathieu, D., & Phan-Tan-Luu, R. (1999). Pharmaceutical experimental design. New York: Marcel Dekker Inc.
19. Li, S., Lin, S., Chein, Y. W., Daggy, B. P., & Mirchandani, H. L. (2001). Statistical optimization of gastric floating system for oral controlled delivery of calcium. AAPS Pharm. Sci. Tech., 2(1), article 1, (http://www.aapspharmsci.org).
20. Li, S., Lin, S., Daggy, B. P., Mirchandani, H. L., & Chein, Y. W. (2003). Effect of HPMC and carbopol on the release and floating properties of gastric floating drug delivery system using factorial design. Int. J. Pharm., 253, 13-22.
21. Lieberman, H. A., Rieger, M. M., & Banker, G. S. (1988). Pharmaceutical dosage forms-Disperse systems. New York: Marcel Dekker Inc.
22. Marshall, K. (1987). Compression and consolidation of powdered solids. In L. Lachman, H. A. Liberman, & J. L. Kanig (Eds.), The theory and practice of industrial pharmacy (p. 67). Mumbai: Varghese Publishing House.
23. Mohamed, S. R., Quadir, M. A., & Haider, S. S. (2003). Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled release drug delivery. J. Pharm. Pharmaceut. Sci., 6(2), 274-291, (www.ualberta.ca/~csps).
24. Mora, P. C., Cirri, M., & Mura, P. (2006). Differential scanning calorimetry as a screening technique in compatibility studies of DHEA extended release formulations. J. Pharm. Biomed. Anal., 42(1), 3-10.
25. Moustafine, R. I., Kemenova, V. A., & Mooter, G. V. (2005). Characteristics of interpolyelectrolyte complexes of Eudragit E 100 with sodium alginate. Int. J. Pharm., 294, 113-120.
26. Moustafine, R. I., Zaharov, I. M., & Kemenova, V. A. (2006). Physicochemical characterization and drug release properties of eudragit EPO/eudragit L100-55 interpolyelectrolyte complexes. Eur. J. Pharm. Biopharm., 65(1), 26-36.
27. Mura, P., Furlanetto, S., Cirri, M., Maestrelli, F., Marras, A. M., & Pinzauti, S. (2005). Optimisation of glibenclamide tablet composition through the combined use of differential scanning calorimetry and D-optimal mixture experimental design. J. Pharm. Biomed. Anal., 37, 65-71.
28. Mutalik, S., & Udupa, N. (2004). Glibenclamide transdermal patches: Physicochemical, pharmacodynamic and pharmacokinetic evaluations. J. Pharm. Sci., 93(6), 1577-1593.
29. Narendra, C., Srinath, M. S., & Babu, G. (2006). Optimization of bilayer floating tablet containing metoprolol tartrate as a model drug for gastric retention. AAPS Pharm. Sci. Tech., 7(2), Article 34, DOI: 10.1208/pt070234.
30. Nath, B. S., Venkatesh, T., & Hiremath, D. (2000). Formulation and evaluation of sustained release dosage form of theophylline using a combined hydrophobic and hydrophilic matrix. Indian J. Pharm. Sci., 62(1), 33-36.
31. Palmar, K. J., & Brogden, R. N. (1993). Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin dependent diabetes mellitus. Drugs, 46, 92-125.
32. Rao, V. M., Engh, K., & Qiu, Y. (2003). Design and pH-independent controlled release matrix tablets for acidic drugs. Int. J. Pharm., 252, 81-86.
33. Sanchez-Lafuente, C., Furlanetto, S., Fernandez-Arevalo, M., Alvarez-Fuentes, J., Rabasco, A. M., Faucci, T., Pinzauti, S., & Mura, P. (2002). Didanosine extended-release matrix tablets: Optimization of formulation variables using statistical experimental design. Int. J. Pharm., 237, 107-118.
34. Singh, B., Sukhwinder, K. C., & Ahuja, N. (2006). Formulation and optimization of controlled release mucoadhesive tablets of atenolol using response surface methodology. AAPS Pharm. Sci. Tech., 7(1), Article 3, DOI: 10.1208/pt070103.
35. Skpoug, J. W., Borin, M. T., Fleishaker, J. C., & Cooper, A. M. (1991). In vitro and in vivo evaluation of whole and half tablets of sustained release adinazolam mesylate. Pharm. Res., 8, 1482-1488.
36. Streubel, A., Siepmann, J., & Bodmeier, R. (2003). Floating matrix tablets based on low-density foam powder: Effects pf formulation and processing parameters on drug release. Eur. J. Pharm. Sci., 18, 37-45.
37. Tadeusz, W. H., Dobrucki, R, Piechocki, S., Resztak, M., & Reh, R. (2005). Pharmaceutical availability of gliclazide from selected matrix formulation tablets. Med. Sci. Monit., 11(6), BR181-188.
38. Tapia-Albarran, M., & Villafuerte-Robles, L. (2004). Effect of formulation and process variables on the release behavior of amoxicillin matrix tablets. Drug Dev. Ind. Pharm., 30(8), 901-908.
39. Timothy, M. E. D., Frank Daly, John, P. W., Kenneth, F. I., John, P. B., & Leon, J. D. (2000). Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian aborigines with type-2 diabetes. J. Clin. Pharmacol., 49, 223-230.
40. Tønnnesen, H. H., & Karlsen, J. (2002). Alginate in drug delivery systems. Drug Dev. Ind. Pharm., 28(6), 621-630.